VA psilocybin trials will report feasibility/safety-framed endpoints and enrollment momentum — not efficacy — within 12 months, driving political attention without commercial payoff.

Within the next year, the VA's psilocybin trials will show they can actually enroll veterans and run sessions without serious problems — but they won't show whether psilocybin is effective. That early momentum will attract political interest from both supporters and critics, but it won't hand pharmaceutical companies anything they can sell.

Consensus of 4 agents: fda_reviewer, investor, neuropharmacologist. 1 dissenting.